Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, with additional target discovery work in autoimmune disorders. The TCRX news page on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how TScan’s programs evolve over time.
News coverage for TCRX often centers on the company’s hematologic malignancies program, particularly TSC-101 and the ALLOHA™ Phase 1 heme trial in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation. Updates include clinical data readouts, such as relapse-free survival and overall survival observations, safety findings, and details on manufacturing process changes for TSC-101. Regulatory milestones, including alignment with the U.S. Food and Drug Administration on a pivotal trial design that mirrors the ALLOHA study, are also key topics in TScan’s press releases.
Investors and observers can also expect TCRX news about the PLEXI-T™ Phase 1 solid tumor trial, the company’s ImmunoBank of therapeutic TCRs, and its strategic decisions to prioritize the heme program while pausing further enrollment in the solid tumor trial. Additional updates highlight the development of in vivo-engineered TCR-T approaches for solid tumors, presentations at scientific meetings such as ASH, ASGCT, and ACR, and TargetScan-based discoveries in T cell-mediated autoimmune disorders.
Financial results, corporate strategy updates, workforce changes, and participation in investor conferences are reported through earnings releases and Form 8-K filings. By reviewing the TCRX news feed, readers gain context on TScan’s clinical progress, regulatory interactions, operational priorities, and research activities across oncology and autoimmunity.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will host a virtual investor event on November 14, 2022, at 5:00 PM ET. This event will review poster presentations from the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting related to their solid tumor TCR-T candidates. TScan's multiplexed therapy aims to address antigen heterogeneity and HLA loss in cancer treatment. Interested participants can register through the provided link, and a replay will be available on TScan’s website.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of a trial in progress abstract for TSC-100 and TSC-101 at the ASH Annual Meeting scheduled for December 10-13, 2022. The poster presentation, titled 'A Phase 1 Umbrella Study of TCR-Engineered T Cells,' will be presented by Dr. Ran Reshef. TSC-100 and TSC-101 are designed to target HA-1 and HA-2 to prevent relapse in AML, ALL, and MDS patients post-allogeneic transplant. The Phase 1 trial is currently open for enrollment, aiming to improve patient outcomes after reduced-intensity conditioning transplants.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of two abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place from November 8–12, 2022, in Boston, MA. The presentations will cover the development of TCR-T therapies targeting MAGEA1 and PRAME to boost therapeutic efficacy, alongside TSC-203-A02, a candidate for treating solid tumors. The company’s ongoing research aims to enhance TCR-T therapeutic options for cancer patients, focusing on both hematologic malignancies and solid tumors.
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical firm, announced participation in two investor conferences. The Jefferies Cell and Genetic Medicine Summit will take place in New York on September 29, 2022, at 1:30 p.m. ET, followed by Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. Both events will feature fireside chats. Webcasts will be available on the company's website, with archived replays accessible for 30 days post-event.
TScan Therapeutics (TCRX), a clinical-stage biopharmaceutical company, announced a $60 million debt financing facility with K2 HealthVentures. The initial $30 million tranche extends its cash runway into Q2 2024, allowing TScan to pursue key milestones in its clinical programs targeting solid tumors and hematologic malignancies. The terms include an interest rate of 8.75% or the Prime Rate plus 4.75%, and the option for K2HV to convert the loan into TScan common shares at approximately $4.785 each. This partnership aims to enhance TScan’s ImmunoBank and clinical trials.
TScan Therapeutics, Inc. (Nasdaq: TCRX) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:55 p.m. ET in New York, NY. The event will be webcasted, and an archived replay will be available on the company’s website for 30 days. TScan focuses on T cell receptor (TCR) engineered therapies for cancer, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies. Their ImmunoBank aids in developing customized therapies for various solid tumors.
TScan Therapeutics, Inc. (TCRX) reported its Q2 2022 results, highlighting a revenue increase to $4.1 million from $2.8 million last year, driven by its collaboration with Novartis. The company ended the quarter with $125.6 million in cash, sufficient to fund operations into 2024. The Phase 1 trial for TCR therapies TSC-100 and TSC-101 is now open for enrollment. TScan anticipates IND filings for TSC-200-A2 and TSC-204-C7 by the end of 2022. However, net losses rose to $15.1 million from $10.7 million in the prior year.
TScan Therapeutics, Inc. (Nasdaq: TCRX), a company focused on T cell receptor (TCR) engineered therapies for cancer, will have its CEO, David P. Southwell, participate in a virtual panel at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 p.m. ET. This discussion titled “A View to a Kill(er Cell)” will delve into advancements in TCR-T therapies. A webcast of the panel will be available on TScan's website, along with an archived replay for 30 days after the event.
The company is developing TCR-T therapies aimed at hematologic malignancies and solid tumors.
TScan Therapeutics (Nasdaq: TCRX) announced the publication of a peer-reviewed article in Cell, showcasing its screening technology that identifies T cell targets in head and neck cancer patients undergoing immunotherapy. The study revealed the TCR engineered candidate TSC-204-C07 targeting MAGE-A1. The research involved 29 patients and was a collaboration with Harvard institutions. TScan aims to file an IND for TSC-204-C07 in late 2022, alongside plans to develop multiplexed TCR therapies for solid tumors. The company positions itself for growth in TCR-T therapies.
TScan Therapeutics, Inc. (TCRX) has appointed Dr. Debora Barton as Chief Medical Officer, bringing nearly 20 years of clinical oncology experience. This appointment coincides with the upcoming Phase 1 trial for leukemia therapy, aimed at treating hematologic malignancies. Dr. Barton previously held key roles at Carisma Therapeutics and Iovance Biotherapeutics, overseeing clinical development and operations. TScan is focused on T-cell receptor engineered therapies, with lead candidates in development targeting both liquid and solid tumors.